Cervical cancer prevention remains a top medical priority for much of the developing world. In order to minimise the gap in screening, availability between the developed and the developing worlds, visual inspection with acetic acid (or VIA) was proposed as a cheap, relatively efficient and easy to implement screening method for low-income settings. As a result, in many developing countries, VIA is the primary step, and the standard, for cervical cancer screening; however, it is rarely corroborated by colposcopy and biopsy. Despite its success, VIA presents a major challenge: with a positive predictive value (PPV) of 17% , five out of six patients receive cryotherapy unnecessarily, as a result of a false positive VIA result. In order to reduce the number of false positives, MobileOCT has developed a mobile colposcope that serves as an adjunct to VIA, while also providing a technological platform that enables high-end multi-modal imaging.